Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Pembrolizumab in Sarcoma
NCT06113809Phase 1Recruiting
- Start
- Feb 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in soft tissue sarcoma (STS). Primary endpoint: Dose Limiting Toxicities and Adverse Events at 4 weeks. Started Feb 2024; status: recruiting.
02
Drugs
palbociclib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06113809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113809.